pan-HER prodrug · small molecule
tarloxotinib
0 active trials across 5 of our biomarkers, targeting pan-HER (hypoxia-activated). Not approved for any biomarker on marked.bio yet.
Also known as TH-4000, tarloxotinib bromide.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| EGFR exon 19 deletion / L858R | 0 | 1 | – |
| EGFR exon 20 insertion | 0 | 1 | – |
| HER2 (ERBB2) activating mutation | 0 | 1 | – |
| KRAS G12C | 0 | 1 | – |
| NRG1 fusion | 0 | 1 | – |
Trials
0 of 3 trials shown
-
Tarlox and Sotorasib in Patients With KRAS G12C Mutations
sotorasib FDA EUtarloxotinib
Histologically confirmed diagnosis of squamous or non-squamous NSCLC with KRAS G12C mutation
KRAS G12CNon-Small Cell Lung Cancer
-
Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions
EGFR exon 20 insertion mutation (Cohort A) or HER2 activating mutation (Cohort B) or NRG1 or ERBB family gene fu…
EGFR exon 20 insertionHER2 (ERBB2) activating mutationNRG1 fusionNSCLC, Stage IV, NSCLC Stage IIIB, NSCLC, Stage IIIC, NSCLC, Recurrent
-
Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients
Documented evidence of an EGFR mutation known to be associated with an EGFR TKI sensitivity
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer, NSCLC, Non-squamous NSCLC
No trials match these filters.